Brief: Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR
03/03/2026 24:43
March 3 (Reuters) - Hua Medicine 2552.HK: APPROVAL OF DORZAGLIATIN FOR MARKETING IN CHINA DORZAGLIATIN APPROVED FOR MARKETING BY PHARMACEUTICAL SERVICE OF DEPARTMENT OF HEALTH OF HONG KONG SAR OF CHINA Further company coverage: 2552.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hua Medicine
See all newsBrief: Hua Medicine Expects Loss Of RMB30.2 Mln For HY
Brief: Hua Medicine Posts Profit For The Year RMB1.11 Billion
Brief: Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR
Brief: Hua Medicine Posts H1 Revenue Of RMB 217.4 Million
Brief: Hua Medicine Expects RMB1,184.1 Million Profit For HY